| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
In the real world clinic, almost all heart failure patients were responders to tolvaptan. In sharp contrast to the previous study, there were a considerable population who had a bad prognosis after long-term administration of tolvaptan in spite of responders. Acute response could be predicted by the ratio of urine AQP2 over plasma AVP >0.5x10^3. but prognostic impact of tolvaptan might need higher ratio of urine AQP2 over plasma AVP. Multivariate analysis revealed that most potent independent risk factor for prognosis was eGFR. Considering that lower eGFR would be associated with lower ratio of urine AQP2 over plasma AVP, those who had a certain level of renal dysfunction might not receive benefit from long-term tolvaptan administration in terms of avoiding re-hospitalizations.
|
